Proposed mechanistic description of dose-dependent BDE-47 urinary elimination in mice using a physiologically based pharmacokinetic model

Toxicology and Applied Pharmacology

Volumn 273, Issue 2, 2013, Pages 335-344

  Emond, Claude ^a,b   Sanders, J Michael ^c   Wikoff, Daniele ^d   Birnbaum, Linda S ^c  

^a BioSimulation Consulting Inc   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c National Cancer Institute   (United States)

^d ToxStrategies   (United States)

Author keywords

BDE 47; M MUP; Mouse; P gp; PBDE; PBPK

Indexed keywords

2,2',4,4' TETRACHLOROBIPHENYL; POLYBROMINATED DIPHENYL ETHER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; INTESTINE; KIDNEY; KIDNEY PROXIMAL TUBULE; MOUSE; NONHUMAN; RAT; RISK ASSESSMENT; URINARY EXCRETION;

2,2′,4,4′-TETRABROMODIPHENYL ETHER; ABC; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE-BINDING CASSETTE; ANALYSIS OF VARIANCE; ANOVA; ATP; BDE-47; FRIEND VIRUS B-TYPE MDR1A/B(+/+) WILD-TYPE (MICE); FRIEND VIRUS B-TYPE MDR1A/B(-/-)-DEFICIENT KNOCKOUT (MICE); FVB-KO; FVB-WT; GASTROINTESTINAL TRACT; GIT; M-MUP; MDR; MOUSE; MOUSE MAJOR URINARY PROTEIN; MRP; MULTI-DRUG RESISTANCE; MULTI-DRUG RESISTANCE-ASSOCIATED PROTEIN; NATIONAL INSTITUTES OF HEALTH; NIH; OAT; OCT; OCTADECYLSILANE; ODS; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; P-GLYCOPROTEIN; P-GP; PBDE; PBPK; PHYSIOLOGICALLY BASED PHARMACOKINETIC; PND; POLYBROMINATED DIPHENYL ETHERS; POSTNATAL DAY; R(T); RETENTION TIME; SA; SD; SENSITIVITY ANALYSIS; STANDARD DEVIATION; T3; T4; THYROXINE; TRIIODOTHYRONINE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOGENATED DIPHENYL ETHERS; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RATS; TISSUE DISTRIBUTION;

ANIMALIA; MUS; RATTUS;

EID: 84888203759     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.09.007     Document Type: Article

References (49)

1. Al-Shawi M.K., Omote H. The remarkable transport mechanism of P-glycoprotein: a multidrug transporter. J. Bioenerg. Biomembr. 2005, 37(6):489-496.
2. Aschengrau A., Rogers S., Ozonoff D. Perchloroethylene-contaminated drinking water and the risk of breast cancer: additional results from Cape Cod, Massachusetts, USA. Environ. Health Perspect. 2003, 111(2):167-174.
3. Bain L.J., LeBlanc G.A. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol. Appl. Pharmacol. 1996, 141(1):288-298.
4. Béliveau M., Krishnan K. Concentration dependency of rat blood: air partition coefficients of some volatile organic chemicals. J. Toxicol. Environ. Health A 2000, 60(6):377-389.
5. Berger F.G. Studies on genetic variation in major urinary protein synthesis in mouse liver. Biochem. Genet. 1983, 21(1-2):15-23.
6. Beynon R.J., Hurst J.L. Multiple roles of major urinary proteins in the house mouse, Mus domesticus. Biochem. Soc. Trans. 2003, 31(Pt. 1):142-146.
7. Birnbaum L.S., Cohen Hubal E.A. Polybrominated diphenyl ethers: a case study for using biomonitoring data to address risk assessment questions. Environ. Health Perspect. 2006, 114(11):1770-1775.
8. Chen S.J., Ma Y.J., Wang J., Chen D., Luo X.J., Mai B.X. Brominated flame retardants in children's toys: concentration, composition, and children's exposure and risk assessment. Environ. Sci. Technol. 2009, 43(11):4200-4206.
9. Cheng X., Maher J., Chen C., Klaassen C.D. Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab. Dispos. 2005, 33(7):1062-1073.
10. Dallaire R., Dewailly E., Pereg D., Dery S., Ayotte P. Thyroid function and plasma concentrations of polyhalogenated compounds in Inuit adults. Environ. Health Perspect. 2009, 117(9):1380-1386.
11. Dunnick J.K., Nyska A. Characterization of liver toxicity in F344/N rats and B6C3F1 mice after exposure to a flame retardant containing lower molecular weight polybrominated diphenyl ethers. Exp. Toxicol. Pathol. 2009, 61(1):1-12.
12. Easterling M.R., Evans M.V., Kenyon E.M. Comparative analysis of software for physiological based pharmacokinetic modeling: simulation, optimization and sensibility analysis. Toxicol. Mech. Methods 2000, 10(3):203-229.
13. Emond C., Charbonneau M., Krishnan K. Physiologically-based modeling of the accumulation in plasma and tissue lipids of a mixture of PCB congeners in female Sprague-Dawley rats. J. Toxicol. Environ. Health A 2005, 68(16):1393-1412.
14. Emond C., Raymer J.H., Studabaker W.B., Garner C.E., Birnbaum L.S. A physiologically based pharmacokinetic model for developmental exposure to BDE-47 in rats. Toxicol. Appl. Pharmacol. 2010, 242(3):290-298.
15. EPA Toxicological review of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47). Support of Summary Information on the Integrated Risk Information System (IRIS) 2008, 1-85. U.S.Environmental Protection Agency, (EPA/635/R-07/005F).
16. Fitzgerald E.F., Shrestha S., Gomez M.I., McCaffrey R.J., Zimmerman E.A., Kannan K., Hwang S.A. Polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs) and neuropsychological status among older adults in New York. Neurotoxicology 2012, 33(1):8-15.
17. Flower D.R. The lipocalin protein family: structure and function. Biochem. J. 1996, 318(Pt. 1):1-14.
18. Hakk H., Larsen G., Bergman A., Orn U. Binding of brominated diphenyl ethers to male rat carrier proteins. Xenobiotica 2002, 32(12):1079-1091.
19. Hites R.A. Polybrominated diphenyl ethers in the environment and in people: a meta-analysis of concentrations. Environ. Sci. Technol. 2004, 38(4):945-956.
20. Hudachek S.F., Gustafson D.L. Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. J. Pharmacokinet. Pharmacodyn. 2013, 40(4):437-449.
21. ILSI Physiological Parameter Values for PBPK Models 1994, 1-120. USEPA.
22. Janotova K., Stopka P. The level of major urinary proteins is socially regulated in wild Mus musculus musculus. J. Chem. Ecol. 2011, 37(6):647-656.
23. Koh T.W., Chih-Cheng Chen S., Chang-Chien G.P., Lin D.Y., Chen F.A., Chao H.R. Breast-milk levels of polybrominated diphenyl ether flame retardants in relation to women's age and pre-pregnant body mass index. Int. J. Hyg. Environ. Health 2010, 213(1):59-65.
24. Kondratov R.V., Komarov P.G., Becker Y., Ewenson A., Gudkov A.V. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(24):14078-14083.
25. Krishnan K., Andersen M. Physiologically based pharmacokinetic modelling in toxicology. Principles and Methods of Toxicology 2008, 231-291. CRC Press, New York. 5th ed. A.W. Hayes (Ed.).
26. Kwak J., Grigsby C.C., Rizki M.M., Preti G., Koksal M., Josue J., Yamazaki K., Beauchamp G.K. Differential binding between volatile ligands and major urinary proteins due to genetic variation in mice. Physiol. Behav. 2012, 107(1):112-120.
27. Larsen G.L., Bergman A., Klasson-Wehler E. A methylsulphonyl metabolite of a polychlorinated biphenyl can serve as a ligand for alpha 2mu-globulin in rat and major-urinary-protein in mice. Xenobiotica 1990, 20(12):1343-1352.
28. Larsen G.L., Bergman A., Wehler E.K., Bass N.M. A methylsulfonyl metabolite of a polychlorinated biphenyl can serve as a ligand for liver fatty acid binding protein in rat intestinal mucosa. Chem. Biol. Interact. 1991, 77(3):315-323.
29. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204(3):216-237.
30. Li N., Hartley D.P., Cherrington N.J., Klaassen C.D. Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. J. Pharmacol. Exp. Ther. 2002, 301(2):551-560.
31. Lin J.H., Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 2003, 42(1):59-98.
32. Maher J.M., Slitt A.L., Cherrington N.J., Cheng X., Klaassen C.D. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab. Dispos. 2005, 33(7):947-955.
33. Mazdai A., Dodder N.G., Abernathy M.P., Hites R.A., Bigsby R.M. Polybrominated diphenyl ethers in maternal and fetal blood samples. Environ. Health Perspect. 2003, 111(9):1249-1252.
34. Mitchell A.M., Tom M., Mortimer R.H. Thyroid hormone export from cells: contribution of P-glycoprotein. J. Endocrinol. 2005, 185(1):93-98.
35. Nukaya M., Takahashi Y., Gonzalez F.J., Kamataki T. Aryl hydrocarbon receptor-mediated suppression of GH receptor and Janus kinase 2 expression in mice. FEBS Lett. 2004, 558(1-3):96-100.
36. Proost J.H., Wierda J.M., Meijer D.K. An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs. J. Pharmacokinet. Biopharm. 1996, 24(1):45-77.
37. Richardson V.M., Staskal D.F., Ross D.G., Diliberto J.J., DeVito M.J., Birnbaum L.S. Possible mechanisms of thyroid hormone disruption in mice by BDE 47, a major polybrominated diphenyl ether congener. Toxicol. Appl. Pharmacol. 2008, 226(3):244-250.
38. Robertson D.H., Cox K.A., Gaskell S.J., Evershed R.P., Beynon R.J. Molecular heterogeneity in the major urinary proteins of the house mouse Mus musculus. Biochem. J. 1996, 316(Pt. 1):265-272.
39. Robertson D.H., Hurst J.L., Bolgar M.S., Gaskell S.J., Beynon R.J. Molecular heterogeneity of urinary proteins in wild house mouse populations. Rapid Commun. Mass Spectrom. 1997, 11(7):786-790.
40. Sanders J.M., Chen L.J., Lebetkin E.H., Burka L.T. Metabolism and disposition of 2,2',4,4'-tetrabromodiphenyl ether following administration of single or multiple doses to rats and mice. Xenobiotica 2006, 36(1):103-117.
41. Sanders J.M., Lebetkin E.H., Chen L.-J., Burka L.T. Disposition of 2,2',4,4',5,5'-hexabromodiphenyl ether (BDE153) and its interaction with other polybrominated diphenyl ethers (PBDEs) in rodents. Xenobiotica 2006, 36(9):824-837.
42. Schecter A., Päpke O., Harris T.R., Tung K.C. Partitioning of polybrominated diphenyl ether (PBDE) congeners in human blood and milk. Toxicol. Environ. Chem. 2006, 88(2):319-324.
43. Schoenborn B.P. Dichloromethane as an antisickling agent in sickle cell hemoglobin. Proc. Natl. Acad. Sci. U. S. A. 1976, 73(11):4195-4199.
44. Sergent T., Ribonnet L., Kolosova A., Garsou S., Schaut A., De S.S., Van P.C., Larondelle Y., Pussemier L., Schneider Y.J. Molecular and cellular effects of food contaminants and secondary plant components and their plausible interactions at the intestinal level. Food Chem. Toxicol. 2008, 46(3):813-841.
45. Sjodin A., Wong L.Y., Jones R.S., Park A., Zhang Y., Hodge C., DiPietro E., McClure C., Turner W., Needham L.L., Patterson D.G. Serum concentrations of polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyl (PBB) in the United States population: 2003-2004. Environ. Sci. Technol. 2008, 42(4):1377-1384.
46. Staskal D.F., Diliberto J.J., Devito M.J., Birnbaum L.S. Toxicokinetics of BDE 47 in female mice: effect of dose, route of exposure, and time. Toxicol. Sci. 2005, 83(2):215-223.
47. Staskal D.F., Diliberto J.J., Birnbaum L.S. Disposition of BDE 47 in developing mice. Toxicol. Sci. 2006, 90(2):309-316.
48. Staskal D.F., Diliberto J.J., Birnbaum L.S. Impact of repeated exposure on the toxicokinetics of BDE 47 in mice. Toxicol. Sci. 2006, 89(2):380-385.
49. Staskal D.F., Hakk H., Bauer D., Diliberto J.J., Birnbaum L.S. Toxicokinetics of polybrominated diphenyl ether congeners 47, 99, 100, and 153 in mice. Toxicol. Sci. 2006, 94(1):28-37.